LEXX Stock Analysis: Buy, Sell, or Hold?
LEXX - Lexaria Bioscience Corp. Common Stock
$10.35
-1.33 (-11.39%)
âŧ
5d:
-5.18%
30d:
+2511.66%
90d:
+1619.27%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Jul 13, 2026
0d
Get Alerted When LEXX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LEXX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LEXX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: LEXX is currently trading at $10.35, which is considered slightly high relative to its 30-day fair value range of $1.74 to $10.43.
Technical Outlook: Technically, LEXX is in a strong uptrend. Immediate support is located at $8.74, while resistance sits at $12.89. Short-term momentum is weak, with the stock down 11.4% recently.
Market Sentiment: LEXX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.50 (+407.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LEXX is in a strong uptrend. Immediate support is located at $8.74, while resistance sits at $12.89. Short-term momentum is weak, with the stock down 11.4% recently.
Market Sentiment: LEXX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.50 (+407.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.74 -
$10.43
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-11.4%)
- BULLISH: Trading 407.2% below Wall St target ($52.50)
- WARNING: Composite score 34/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.74 -
$10.43
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.74
Resistance Level
$12.89
Current Trend
Strong Uptrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.23
Wall Street Target
$52.50
(+407.2%)
Revenue Growth (YoY)
-88.5%
Share & Embed Analysis
Last updated: August 29, 2026 10:42 PM ET
Data refreshes hourly during market hours. Next update: 11:42 PM
Data refreshes hourly during market hours. Next update: 11:42 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LEXX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 29 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 31 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 43 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 46 HOLD |
